Press Releases

September 20, 2016

Diabetes Drug Development Is Riskier Compared to All Drug Development

Whereas scores of new diabetes and non-diabetes endocrine drugs have been launched since the mid-1990s, and the demand for new therapies continues to grow, the development process for new diabetes and non-diabetes endocrine drugs is riskier compared to all drug development, according to results of a new study conducted by the Tufts Center for the Study of Drug Development.

Learn More....

July 14, 2016

Global Regenerative Medicine Market Is Poised for Strong Growth

A strong development pipeline for regenerative medicine (RM) therapies aimed at treating a broad range of unmet medical needs signals rapid growth in global RM product sales that could have significant and positive impacts on public health, according to a newly completed analysis by the Tufts Center for the Study of Drug Development.

Learn More....

May 10, 2016

Expected Growth in PBM Exclusion Lists Poses a Challenge to Drug Developers

Rising drug prices in the United States will lead payers and pharmaceutical benefit managers (PBMs) to increase the number of drugs ineligible for reimbursement, which will challenge drug developers to provide more concrete evidence of clinical superiority and cost-effectiveness of their products, according to a newly completed analysis by the Tufts Center for the Study of Drug Development.

Learn More....

March 10, 2016

Tufts CSDD Assessment of Cost to Develop and Win Marketing Approval for a New Drug Now Published

The most recent analysis by the Tufts Center for the Study of Drug Development of the average cost to develop and gain marketing approval for a new drug—pegged at $2.558 billion—has been published in the Journal of Health Economics, it was announced today.

Learn More....

March 8, 2016

Promise of Immuno-Oncology Therapies Is Boosting R&D Funding and Alliances

Investments in research and development for new immuno-oncology (I/O) drugs, along with dramatic improvements in complete response rates in trials for new I/O therapies, are helping to increase the number of alliances between pharmaceutical and biotech companies and university and cancer centers, a new analysis by the Tufts Center for the Study of Drug Development shows.

Learn More....

January 26, 2016

New Approaches to Patient Recruitment and Retention Anticipate Structural Change in the Clinical Research Enterprise

Responding to strong and growing pressures to accelerate the pace at which new medicines are launched, drug developers are innovating clinical study volunteer recruitment and retention to significantly improve clinical trial performance and efficiency, according to R&D leaders participating in a roundtable recently hosted by the Tufts Center for the Study of Drug Development.

Learn More....

January 14, 2016

Protocol Amendments Improve Elements of Clinical Trial Feasibility, But at High Economic and Cycle Time Cost

Research sponsors implement at least one substantial global amendment for nearly 60% of all clinical trial protocols, substantially reducing the number of actual patients screened and enrolled, but leading to significantly longer clinical trial durations and higher costs, a newly completed analysis by the Tufts Center for the Study of Drug Development concludes.

Learn More....

January 7, 2016

Drug Developers Are Working to Boost R&D Productivity, But Need to do More to Achieve Large-Scale Improvements

While drug developers during the coming year will continue their efforts to meet the growing demand for innovative new medicines, they must also significantly scale up their level of process improvements if they are to reduce the time and cost required to bring new drugs to market, according to the Tufts Center for the Study of Drug Development.

Learn More....

November 3, 2015

Nearly All Later Entrants to Drug Classes Were in Clinical Testing or Regulatory Review Before First-in-Class Approval

Nearly all later entrants to drug classes had begun clinical testing or were in regulatory review in the United States before the first drug within a pharmacologic class was approved, a newly completed analysis from the Tufts Center for the Study of Drug Development suggests.

Learn More....

October 20, 2015

Innovation in Drug Development Process Remains a Key Challenge

Although pharmaceutical companies have long aspired to improve drug development efficiency, the drug development process remains highly inefficient and fraught with delays and rising costs, according to R&D leaders participating in a roundtable recently hosted by the Tufts Center for the Study of Drug Development.

Learn More....

September 16, 2015

Adverse Drug Event Reporting in U.S. Beset by Incompleteness and Inaccuracy

Adverse Drug Event Reporting in U.S. Beset by Incompleteness and Inaccuracy, According to the Tufts Center for the Study of Drug Development

Learn More....

August, 19, 2015

Personalized Medicine Development Tied to Showing Value of Companion Diagnostics

With interest in personalized medicines growing, drug and diagnostics companies are investing in the development of companion diagnostics that can show that their use in conjunction with personalized therapeutics will lead to positive health outcomes, according to R&D leaders participating in a roundtable recently hosted by the Tufts Center for the Study of Drug Development.

Learn More....

July 9, 2015

Vaccine Products in Development Have Tripled over Last Decade

Vaccine products in the R&D pipeline have more than tripled since 2005 and annual worldwide sales are on track to reach $40 billion by 2020, according to a recently completed study by the Tufts Center for the Study of Drug Development.

Learn More....

June 23, 2015

New Tufts CSDD Report Profiles New R&D Cross-Functional Approaches Driving Higher Levels of Efficiency

The Tufts Center for the Study of Drug Development (CSDD) announces the release of a new report highlighting innovative approaches across the R&D continuum that pharmaceutical companies are implementing to drive efficiency and lower cost.

Learn More....

May 14, 2015

Personalized Medicine Is Gaining Traction, but Faces Multiple Challenges

While development of personalized medicines has grown since the human genome was first sequenced in 2001, biopharmaceutical sponsors face a number of hurdles that are impeding more rapid market uptake, according to a recently completed study by the Tufts Center for the Study of Drug Development.

Learn More....

April 14, 2015

Early BTD Projects Offer Lessons for Drug Companies

Flexibility and a willingness to learn from each other are key factors that enable drug companies and regulators to engage successfully in development projects that have been accorded breakthrough therapy designation, or BTD, according to R&D executives participating in a roundtable recently hosted by the Tufts Center for the Study of Drug Development

Learn More....

March 5, 2015

U.S. Biosimilar Approvals Poised to Grow, but Market Uptake Faces Several Challenges

Biosimilar approvals in the United States are expected to increase during the next five years, but safety concerns among physicians and the need for greater regulatory clarity concerning therapeutic interchangeability could hinder market uptake, according to a study recently completed by the Tufts Center for the Study of Drug Development.

Learn More....

February 18, 2015

The Evolution Of Biotechnology And Its Impact On Health Care

In this article we examine the evolution of biotechnology during the past three decades and the profound impact that it has had on health care through four interrelated and interdependent tracks: innovations in science, government activity, business development, and patient care.

Learn More....

January 29, 2015

Sponsors and CROs Implementing New Ways to Better Leverage Investigative Site Relationships

Improved investigative site relationship use and effectiveness are top objectives in 2015 for pharmaceutical companies and contract research organizations, according to drug industry R&D executives participating in a roundtable recently hosted by the Tufts Center for the Study of Drug Development.

Learn More....

January 15, 2015

High Turnover and Protocol Noncompliance Continue to Plague the Global Investigative Site Landscape

Global clinical trial performance and efficiency are hampered by high turnover and noncompliance among principal investigators and wide variation in investigative site experience, according to a recently completed assessment by the Tufts Center for the Study of Drug Development.

Learn More....

January 12, 2015

Report from Almac Confirms ePRO Benefits Outweigh Paper-Based Alternative for Clinical Trials

Almac Group, a global leader in technology and services for the pharmaceutical and biotech industries announced the results of a survey conducted by researchers at the Tufts Center for the Study of Drug Development, outlining the perceptions and anticipated implementation of electronic Patient Reported Outcome (ePRO) methods used in conducting clinical trials.

Learn More....

January 8, 2015

Drug Sponsors Challenged to Contain Health Care Costs while Boosting Productivity

Drug developers will implement strategies over the next year to improve clinical study performance to help control R&D costs and boost overall productivity, while increasing their focus on the development of cost-effective therapies that can help lower health care spending, according to the Tufts Center for the Study of Drug Development.

Learn More....

November 18, 2014

Cost to Develop and Win Marketing Approval for a New Drug Is $2.6 Billion

Developing a new prescription medicine that gains marketing approval, a process often lasting longer than a decade, is estimated to cost $2,558 million, according to a new study by the Tufts Center for the Study of Drug Development.

Learn More....

November 4, 2014

CNS Drugs Take Longer to Develop and Have Lower Success Rates than Other Drugs

Drugs that treat central nervous system (CNS) diseases take more than a year longer to develop and are less than half as likely to obtain marketing approval than other drugs, according to a newly completed study by the Tufts Center for the Study of Drug Development.

Learn More....

October 9, 2014

Drug Companies Outline Ways Strategic Partnerships Can Boost Innovation

Strategic relationships between drug developers and contract research organizations(CROs) are generating innovative approaches to clinical trial design and execution, but creating lasting value for both parties requires them to act in new ways, R&D executives from the pharmaceutical and biotech industry said at a gathering recently hosted by the Tufts Center for the Study of Drug Development.

Learn More....

September 9, 2014

Protocol Design Optimization Is Starting to Improve Clinical Study Performance

Efforts by drug companies to streamline and improve the execution of clinical study designs—to counter mounting costs and shorten development times associated with bringing new drugs to market—are yielding positive benefits, according to an assessment recently completed by the Tufts Center for the Study of Drug Development.

Learn More....

August 7, 2014

Drug Company Collaborations to Reduce Development Risk Are Increasing

As pharmaceutical and biotech companies look to speed development, lower cost, and reduce technical risks associated with new drug development, they are increasing the number and types of collaborative relationships they are forming with other developers, as well as with service providers and other stakeholders, according to the Tufts Center for the Study of Drug Development.

Learn More....

July 10, 2014

Orphan Drug Approvals Have Increased, But High Costs Pose Challenges for Patients

Although the pace of approvals for new orphan drugs—medicines that treat relatively rare conditions—have increased in the United States and Europe in recent years, patients are facing growing challenges accessing those drugs, a newly completed study by the Tufts Center for the Study of Drug Development at Tufts University has concluded.

Learn More....

May 8, 2014

Risk-Sharing Drug Development Programs Experience Longer Development Times

Drug development programs that involve several partners who share clinical development risks accounted for about half of all new therapeutic drug approvals in recent years and experienced longer clinical phase times, as well as longer overall time to approval, according to a study recently completed by the Tufts Center for the Study of Drug Development.

Learn More....

April 15, 2014

Drug Developers Are Using New Models and Methods to Boost Clinical Success Rates

Drug companies and their development partners who are seeking to increase clinical success rates of new drug candidates are developing tools to help them predict the likelihood of marketing approval and incorporating business planning earlier in clinical development, according to R&D leaders who recently participated in a roundtable discussion convened by the Tufts Center for the Study of Drug Development.

Learn More....

March 6, 2014

Drug Developers Circumspect about Using Social Media in Clinical Research

Social media is gaining ground as an important tool to improve the clinical research process through more effective engagement of patient communities, but drug sponsors are proceeding cautiously, according to an analysis recently completed by the Tufts Center for the Study of Drug Development.

Learn More....

January 23, 2014

New Breakthrough Therapy Designation Has Potential to Shorten Development Time Considerably

The recently launched Breakthrough Therapy Designation (BTD) program in the United States, aimed at expediting development and review of drugs intended to treat a serious condition, has the potential to shorten development time considerably, according to the Tufts Center for the Study of Drug Development, which recently completed an assessment of the BTD program.

Learn More....

January 16, 2014

Drug Developers Are Implementing New Strategies for Use of Comparator Drugs in Clinical Trials

Drug developers are aggressively implementing new strategies to improve their access to and use of comparator drugs, which are used in clinical trials to determine how development candidates compare to existing therapies, according to leaders from the research-based drug industry who recently participated in a roundtable discussion convened by the Tufts Center for the Study of Drug Development.

Learn More....

January 7, 2014

Drug Company Success Depends on New Development Paradigms

While many drug developers continue to improve clinical trial operational efficiency to increase the pace of new product introductions, their medium- and long-term success increasingly will depend on their ability to embrace more efficient R&D models, according to the Tufts Center for the Study of Drug Development.

Learn More....

November, 14, 2013

Biotech Products in Big Pharma Clinical Pipelines Have Grown Dramatically

The pharmaceutical industry, especially Big Pharma, has dramatically shifted its R&D focus from its historical concentration on small molecule drugs to include a rapidly increasing number of biotechnology products, according to a newly completed analysis from the Tufts Center for the Study of Drug Development.

Learn More....

October 8, 2013

Drug Sponsors & Their External Service Partners Say Adjusting Relationship Models Offers a Path to Greater Performance...

While drug sponsor use of strategic relationships with contract service providers has increased dramatically during the past five years, improvements in clinical trial efficiency has fallen short, suggesting that both parties need to better align practices, processes, and systems, according to leaders from the research-based drug industry, recently convened by the Tufts Center for the Study of Drug Development to discuss the issue.

Learn More....

September 10, 2013

Clinical Study Failures Vary Widely by Phase of Study and Therapeutic Class

While lack of commercial viability is the leading cause of Phase I failures for new drug candidates, efficacy issues dominate as the reason for Phase II failures, according to a new analysis from the Tufts Center for the Study of Drug Development.

Learn More....

August 13, 2013

Drug Industry Leaders See Collaboration as Key to Greater Productivity

Responding to a widely shared need to improve the probability of R&D success, leaders from the research-based drug industry, recently convened by the Tufts Center for the Study of Drug Development, agreed that collaboration holds strong promise for improving the rate at which much needed medicines can be developed and brought to market.

Learn More....

July 11, 2013

Number of Annual New Drug Approvals to Treat Neglected Diseases Has Nearly Doubled Between the Early-2000s and 2009-12

The annual number of new drug approvals worldwide to treat neglected diseases has nearly doubled in recent years, with HIV/AIDS and malaria drugs accounting for 60 percent of the most recent approvals, according to a newly completed analysis from the Tufts Center for the Study of Drug Development.

Learn More....

May 7, 2013

Clinical Success Rates for New Cancer Drugs Doubled from the Mid-1990s to Early-2000s

Clinical success rates for new cancer drugs doubled between the mid-1990s to the early 2000s, while the number of new cancer drugs entering clinical testing increased 50 percent during the same time, according to an analysis recently completed by the Tufts Center for the Study of Drug Development.

Learn More....

April 9, 2013

New Protocol Design Approaches Will Improve Clinical Trial Performance and Efficiency

Growing protocol complexity - responsible for longer clinical study times, greater difficulty in recruiting volunteers, and rising drug development costs - is spurring new approaches to optimizing protocol design, according to leaders from the research-based drug industry recently convened by the Tufts Center for the Study of Drug Development.

Learn More....

March 12, 2013

Investigative Site Landscape Remains Highly Fragmented as the Number of Active Investigators Worldwide Reaches an All-time High

Investigative Site Landscape Remains Highly Fragmented as the Number of Active Investigators Worldwide Reaches an All-time High, According to the Tufts Center for the Study of Drug Development

Learn More....

January 24, 2013

Companion Diagnostics, Key to Development of Personalized Medicines, Face Hurdles

Companion diagnostics, which are central to the creation of personalized medicines, have captured the interest of many drug companies, but face a number of hurdles that could impede development, according to a panel of leaders from the research-based drug industry recently convened by the Tufts Center for the Study of Drug Development.

Learn More....

January 15, 2013

New Research from Tufts [CSDD] Characterizes Effectiveness and Variability of Patient Recruitment and Retention Practices

While nine out of 10 clinical trials worldwide meet their patient enrollment goals, reaching those targets typically means that drug developers need to nearly double their original timelines, according to new research from the Tufts Center for the Study of Drug Development, benchmarking patient recruitment and retention practices.

Learn More....

January 8, 2013

Drug Developers Need to More Fully Identify and Address Root Causes of R&D Inefficiency

While patent expirations on many top selling medicines is spurring the research-based drug industry to embrace new development paradigms to replenish sparse R&D pipelines, drug developers need to more fully identify and address root causes of R&D inefficiency, according to the Tufts Center for the Study of Drug Development.

Learn More....

November 6, 2012

Extraneous Data Collected in Clinical Trials Cost Drug Developers $4 Billion to $6 Billion Annually

One out of every five procedures performed during later stage clinical trials collects extraneous data and costs drug developers more than $1 million per trial, a newly completed study by the Tufts Center for the Study of Drug Development has found.

Learn More....

October 17, 2012

Contract Support and Technical Service Providers Expected to Play a Growing Role in Drug Development

Drug sponsors and their contract service providers are using more sophisticated, integrated, and coordinated relationship structures to deliver greater speed and efficiency, a trend that is expected to accelerate, according to a panel of leaders from the research-based drug industry recently convened by the Tufts Center for the Study of Drug Development.

Learn More....

September 5, 2012

Oncology Drugs Get Faster Approvals than Non-Oncology Drugs in U.S., But the Opposite is True in the EU

Approval times for new oncology drugs in the United States during the last decade were shorter than approval times for non-oncology products, while the reverse was the case in the European Union, according to a study recently completed by the Tufts Center for the Study of Drug Development.

Learn More....

August 7, 2012

Drug Companies Are Teaming with Academic Medical Centers to Create New Medicines

Drug developers are forging new ways to work with academic medical centers to create the next generation of breakthrough medicines, which is changing the way drug companies do science, according to a panel of leaders from the research-based drug industry recently convened by the Tufts Center for the Study of Drug Development.

Learn More....

July 10, 2012

U.S. Cancer Patients Get Faster Access to More Oncology Drugs than European Patients

Cancer patients in the United States get faster access to more oncology drugs to treat their disease than patients in Europe, according to a newly completed study by the Tufts Center for the Study of Drug Development.

Learn More....

May 9, 2012

Drug Sponsors' Regulatory Experience Was Mixed During PDUFA IV

Drug sponsors experienced a mixed regulatory burden under the FDA Amendments Act, which was also the fourth iteration of the Prescription Drug User Fee Act (PDUFA IV), according to new research from the Tufts Center for the Study of Drug Development.

Learn More....

April 26, 2012

Drug Companies Are Looking to Shorten Time to Early Clinical Development

Drug companies looking to increase the efficiency and productivity of their R&D pipelines are turning to a host of techniques and approaches aimed at shortening the time from nonclinical to early clinical development

Learn More....

Mar. 6, 2012

Drugs to Treat CNS Diseases Take 35% Longer to Develop than Other Drugs

Drugs developed to treat central nervous system (CNS) diseases take 35% longer to complete clinical trials and receive regulatory approval compared to other new prescription medicines, according to an analysis recently completed by the Tufts Center for the Study of Drug Development.

Learn More....

January 26, 2012

Drug Company Executives Are Expanding Their Use of Strategic Partnerships

Pharmaceutical and biopharmaceutical companies, under pressure to increase R&D productivity, are expanding their use of strategic partnerships to bring new drugs to market more quickly and at lower cost, according to a panel of leaders from the research-based drug industry recently convened by the Tufts Center for the Study of Drug Development.

Learn More....

Jan. 17, 2012

Tufts [CSDD] Establishes Workload and Utilization Benchmarks for Global Clinical Research Associates

The Tufts Center for the Study of Drug Development today announced that it has established the first global benchmark for clinical research associate (CRA) workload and utilization, giving managers insights into improving CRA effectiveness and efficiency.

Learn More....

January 5, 2012

Drug Companies Are Taking Steps to Improve R&D Productivity

Although drug companies are pursuing innovative approaches to increase the pace and reduce the cost of drug development, the greatest advances will come from better coordination with development partners and improved clinical trial design, according to the Tufts Center for the Study of Drug Development.

Learn More....

Nov. 8, 2011

Number of Monoclonal Antibody Products in Development Continues to Increase

Developers are steadily increasing the number of monoclonal antibody products

Learn More....

October 6, 2011

Drug Companies Are Using Innovative Partnerships to Spur Development

Responding to strong and growing pressure to reduce development times and increase the output of new medicines, drug companies are engaging in innovative partnerships that are leading to, among other things, more molecular entities entering Phase I trials and shorter study times, according to a panel of leaders from the research-based drug industry recently convened by the Tufts Center for the Study of Drug Development.

Learn More....

Sept. 13, 2011

Majority of Clinical Trial Protocols Are Amended, But One-Third of Those Changes Are Avoidable

Nearly 60 percent of all protocols used in clinical trials for new drugs are amended during the trial. Moreover, one-third of those changes could have been avoided, according to the first-ever analysis, conducted by the Tufts Center for the Study of Drug Development, quantifying the impact of protocol changes on clinical trials.

Learn More....

August 9, 2011

Management Implications of the Global Regulatory Environment

As pharmaceutical and biopharmaceutical companies increase the number of clinical trials they conduct in emerging global markets, growing regulatory complexity is forcing them to change the way they operate, according to a panel of leaders from the research-based drug industry recently convened by the Tufts Center for the Study of Drug Development.

Learn More....

July 19, 2011

Lack of Clinically Useful Diagnostics Hinder Growth in Personalized Medicines

Lack of evidence that links diagnostic tests to health outcomes has led payers in the United States to be skeptical about the clinical usefulness of those tests and is hindering the growth of personalized medicines, according to a newly completed analysis by the Tufts Center for the Study of Drug Development.

Learn More....

May 10, 2011

Biotech Drug Approvals in the U.S. Nearly Doubled in the Last Decade

U.S. regulatory approvals for new biopharmaceuticals nearly doubled in the last decade, compared to the 1990s, according to the Tufts Center for the Study of Drug Development, but drug developers "face substantial challenges" if they are to maintain that pace, the study's author says.

Learn More....

April 26, 2011

Drug Developers Actively Improving Efficiency of Clinical Trials

Looking to improve the operational efficiency of clinical trials, drug developers are actively pursuing new strategies that include collaborating with investigative sites in developing protocols and educating patients about trials before they agree to participate, according to a panel of leaders from the research-based drug industry recently convened by the Tufts Center for the Study of Drug Development.

Learn More....

March 8, 2011

U.S. Approvals of Supplemental Drug Indications Have Been Rising Steadily

New or modified indication approvals for existing prescription drugs have steadily increased in the United States since the late 1990s, according to an analysis recently completed by the Tufts Center for the Study of Drug Development.

Learn More....

January 27, 2011

Translational Science Expected to Play a Growing Role in Creating New Drugs

To produce drug candidates at the pace needed to remain competitive, pharmaceutical and biotech companies increasingly are using translational science to make decisions about what targets to pursue and how to allocate resources, according to a panel of pharmaceutical and biotech industry leaders and academics recently convened by the Tufts Center for the Study of Drug Development.

Learn More....

January 12, 2011

U.S. Healthcare Stakeholders Uncertain about Benefits of Risk Evaluation Program

Drug developers, healthcare providers, insurance companies, and others involved in the delivery of healthcare in the United States are uncertain about the benefits of a risk evaluation program introduced three years ago by the Food and Drug Administration (FDA), according to the Tufts Center for the Study of Drug Development.

Learn More....

November 16, 2010

Personalized Medicines Are Shaping the Way R&D Is Done, According to Tufts Center for the Study of Drug Development

Personalized medicine development, occupying a growing role in the clinical pipelines of drug developers, is leading companies to change their R&D paradigms, including how they make go/no-go decisions, according to a recently completed study by the Tufts Center for the Study of Drug Development.

Learn More....

October 26, 2010

Pharma and Biotech Firms Are Rethinking Their Approach to Outsourcing

The current business climate is challenging pharmaceutical and biotech companies to rethink their approach to outsourcing and how best to build alliances with external service providers as part of a long term drug development strategy, according to a panel of pharmaceutical and biotech industry leaders recently convened by the Tufts Center for the Study of Drug Development.

Learn More....

September 9, 2010

Approval Success Rates Higher for Smaller Firms Among Top 50 Pharmaceutical Companies

The top 10 pharmaceutical companies out of the world's top 50 have lower estimated overall clinical approval success rates than do smaller firms in that group, but nonetheless appeared to have some R&D productivity advantages, according to a new study completed by the Tufts Center for the Study of Drug Development.

Learn More....

August 11, 2010

Portfolio Management Is Key to Improved Drug Development Productivity

Drug developers need to change the way they allocate resources for new product development, lifecycle management, and business development and licensing—collectively known as portfolio management—if they are to improve drug development productivity, according to a panel of pharmaceutical and biotech industry leaders recently convened by the Tufts Center for the Study of Drug
Development.

Learn More....

July 8, 2010

Comparative Effectiveness Research Could Alter Pharmaceutical Care in the United States

Comparative effectiveness research, which assesses the relative strengths and weaknesses of various medical interventions, could help close the gap between what is known and what is done in pharmaceutical care in the United States, according to the Tufts Center for the Study of Drug Development, which recently completed an analysis on the matter.

Learn More....

April 6, 2010

New Approaches to R&D May Prove Best Path for Drug Developers

Innovative approaches to drug development, including alliances and partnerships, may prove the best way to increase the rate at which the research–based drug industry brings new products to market, according to a panel of pharmaceutical and biotech industry leaders recently convened by the Tufts Center for the Study of Drug Development.

Learn More....

March 11, 2010

Regulatory Affairs Workload at Drug Development Firms Has Increased Dramatically

A growing volume of global drug development and commercialization activity during the past decade has dramatically increased the workload for regulatory affairs professionals at pharmaceutical and biotech companies, according to a study recently completed by the Tufts Center for the Study of Drug Development.

Learn More....

January 28, 2010

Tufts Center for the Study of Drug Development Launches New Website

The Tufts Center for the Study of Drug Development, the world's leading, independent authority on the nature and pace of pharmaceutical and biotech drug development, today announced the launch of its new website that makes it easier for industry professionals and others to research critical drug development issues.

Learn More....

January 26, 2010

Capacity Planning Is Becoming a Critical Success Factor for Drug Developers

Growing pressure within the research-based drug industry to bring new products to market faster and more efficiently is transforming clinical trial capacity planning and forecasting from an important area of concern to a critical success factor.

Learn More....

January 20, 2010

U.S. Orphan Product Designations More than Doubled During Last Decade

The number of orphan product designations in the U.S. more than doubled during the last decade, reflecting growing interest by pharmaceutical and biotech companies in developing products to treat orphan diseases.

Learn More....

January 6, 2010

Drug Companies Still Under Pressure to Increase Pace of Development

Although drug developers are improving R&D efficiency, in part by terminating more unpromising drugs earlier in development, their continued success will depend on how well they partner with other firms at specific points on the development spectrum, according to the Tufts Center for the Study of Drug Development.

Learn More....

November 17, 2009

New Products to Treat Neglected Diseases Are on the Rise

New products to treat neglected diseases have received marketing approval from regulatory agencies at a steadily increasing rate in recent years as R&D funding for those diseases has increased.

Learn More....

September 9, 2009

Marketing Exclusivity for First -in-Class Drugs Has Shortened to 2.5 Years

Marketing exclusivity periods for first-in-class drugs have fallen dramatically in recent decades - from a median of 10.2 years in the 1970s to 2.5 years in the early part of this decade - underscoring the competitive nature of drug development, a new study recently completed by the Tufts Center for the Study of Drug Development has found.

Learn More....

July 8, 2009

Large Pharmaceutical Firms Are Getting More Drugs Into Development While Terminating Unpromising Candidates

Large pharmaceutical firms, under pressure to bring new medicines to market faster, have been getting more drug candidates into development in recent years and have become more aggressive in terminating unpromising candidates.

Learn More....

May 20, 2009

Number of Therapeutic Peptides in Clinical Study Has Nearly Doubled Since the 1990s

Since 2000, the number of therapeutic peptides in clinical study have nearly doubled the 1990s rate, due in part to advances in synthesis, delivery, and formulation technologies.

Learn More....

ABOUT RESEARCH COURSES & FORUMS LIBRARY & BIBLIOGRAPHY REPORTS SPONSORED RESEARCH NEWS